article thumbnail

Article Periodic Thank You European Commission unveils proposed ban on bisphenol A in food packaging

Agency IQ

European Commission unveils proposed ban on bisphenol A in food packaging The European Commission has proposed a total ban on bisphenol A and related substances for use in food contact materials. ng/kg of body weight for the substance, or roughly 20,000 times lower than the 2015 provisional TDI of 4 mcg/kg (or 4 000 ng/kg) of body weight.

article thumbnail

FDA Issues Long-Awaited QMSR Final Rule

FDA Law Blog: Biosimilars

This amendment marks the first significant revision of Part 820 since 1996, which established the Quality System (QS) regulation and “included requirements related to the methods used in, and the facilities and controls used for, designing, manufacturing, packaging, labeling, storing, installing, and servicing of devices intended for human use.”

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

eMDR System Enhancements

FDA Law Blog: Biosimilars

Since the final rule took effect on August 14, 2015, medical device manufacturers and importers have been required to submit MDRs in an electronic format. For any major changes, additional time will be granted between the release of the implementation package and production deployment.

article thumbnail

Sandoz Application for proposed biosimilar adalimumab’s high concentration formulation accepted by EMA

The Pharma Data

As part of the comprehensive submission package to the EMA, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing Hyrimoz 50 mg/mL 2 and Hyrimoz HCF. 2,3 In 2015, the EMA and US FDA approved Humira ® HCF, which contains adalimumab at a concentration of 100 mg/mL.

article thumbnail

Next steps in our web applications' architecture

The Open Targets Blog

A brief history of our Front-end ecosystem We launched the Open Targets Platform at the end of 2015. The use of OT-UI was complicated by issues such as handling third-party library versions, developing in a local environment using NPM (node package manager), and integrating custom components.

article thumbnail

Q&A: The IND Journey Phase I – Navigating Success

Advarra

Q: What is the typical time period between the submission of the briefing package and the pre-IND meeting? A: The FDA’s guidance document indicates the briefing package is submitted four weeks before the meeting. Q: The speaker just stated that the Meeting Package is due 60 days before the meeting date. of this guidance.

article thumbnail

Reinventing the small molecule toolbox: from proteins to RNA

Dark Matter Blog

Prior to 2015, I had a casual relationship, at best, with targeting RNA. Targeting RNA is a Whole New World Then in 2015, I became smitten and eloped with RNA, setting out to build a company devoted to bringing to bear industrial drug discovery concepts and methods on a new problem of drugging RNA with small molecules.